Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

AstraZeneca

Status: Completed

Conditions: Coronary Heart Disease; Hypercholesterolemia

Study type: Observational

Funder types: Industry

Identifiers

NCT00396110

25V06

TARGET

Details and patient eligibility

About

In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C < 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• High-risk patients with and without evident CHD who had LDL-C > 3.2 mmol/l and were treated at that moment with HMG-CoA-reductase inhibitor apart from rosuvastatin.
• Patients were aged >18 years and <70 years (men) and < 75 years (women).

Exclusion criteria

• Treatment with atorvastatin 40 or 80 mg or simvastatin 80 mg
• Patients familiar with muscular pain, myopathy or liver function disorders (inclusive elevation of serum transaminases) and/or contra-indications for treatment with rosuvastatin